GO:0003851 N-acylsphingosine galactosyltransferase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0003851 describes the enzymatic activity that transfers galactose from UDP-alpha-D-galactose to N-acylsphing-4-enine (ceramide), producing beta-D-galactosyl-(1<->1')-N-acylsphing-4-enine (galactosylceramide) and UDP.
• The enzyme responsible, ceramide galactosyltransferase (CGT, encoded by UGT8), is critical for the synthesis of galactosylceramide and its sulfated derivative sulfatide, major components of myelin in the nervous system.
• CGT expression is tightly regulated by transcription factors such as Nkx2.2 (positive) and OLIG2 (negative), influencing myelination and remyelination processes.
• Defects in galactosylceramide synthesis are linked to demyelinating diseases and altered cholesterol biosynthesis in Schwann cells.
• Research on GO:0003851 employs knockout, point-mutation, knock-in, and overexpression models to dissect its role in myelination and disease.
• EDITGENE provides CRISPR-based services to generate such models, enabling precise functional studies of UGT8 and related genes.
Description
N-acylsphingosine galactosyltransferase activity (GO:0003851) is a molecular function that catalyzes the transfer of galactose from UDP-alpha-D-galactose to ceramide, forming galactosylceramide, a key sphingolipid in myelin. This activity is essential for the development and maintenance of the nervous system, as galactosylceramide and its sulfated form, sulfatide, are major lipid components of myelin sheaths. The enzyme responsible, ceramide galactosyltransferase (CGT), is encoded by the UGT8 gene in humans. Understanding this activity is crucial for researchers studying myelination, demyelinating diseases, and lipid metabolism. The reaction also produces UDP and a proton, and its proper regulation is vital for normal brain function.
N-acylsphingosine galactosyltransferase activity At A Glance
| GO ID | GO:0003851 |
|---|---|
| GO term | N-acylsphingosine galactosyltransferase activity |
| Ontology | molecular_function |
| Synonym | 2-hydroxyacylsphingosine 1-beta-galactosyltransferase activity |
| Major function | Transfer of galactose to ceramide to form galactosylceramide |
| Reaction | N-acylsphing-4-enine + UDP-alpha-D-galactose = beta-D-galactosyl-(1<->1')-N-acylsphing-4-enine + H+ + UDP |
| Enzyme | Ceramide galactosyltransferase (CGT), encoded by UGT8 |
| Localization | Endoplasmic reticulum and Golgi apparatus (implied from enzyme function) |
| Pathway | Sphingolipid biosynthesis, galactosylceramide and sulfatide synthesis |
What Is GO:0003851?
N-acylsphingosine galactosyltransferase activity is defined as the catalysis of the reaction: N-acylsphing-4-enine (ceramide) + UDP-alpha-D-galactose = a beta-D-galactosyl-(1<->1')-N-acylsphing-4-enine (galactosylceramide) + H+ + UDP. This activity belongs to the molecular_function ontology and is synonymous with 2-hydroxyacylsphingosine 1-beta-galactosyltransferase activity.
Why Is N-acylsphingosine galactosyltransferase activity Important in Cell Biology?
N-acylsphingosine galactosyltransferase activity is fundamental for the synthesis of galactosylceramide and sulfatide, which are indispensable for the structure and function of myelin in the central and peripheral nervous systems. Disruptions in this activity lead to severe neurological defects, including demyelination and impaired nerve conduction. Moreover, the enzyme's expression is developmentally regulated and influenced by transcription factors that control myelination. Studying this activity provides insights into demyelinating diseases such as multiple sclerosis and leukodystrophies, and it is a target for therapeutic strategies aimed at promoting remyelination.
• Essential for myelin sheath formation and maintenance in the nervous system.
• Defects cause demyelination and neurological disorders.
• Regulated by transcription factors Nkx2.2 and OLIG2, linking to oligodendrocyte differentiation.
• Involved in cholesterol biosynthesis regulation in Schwann cells.
• Target for research on multiple sclerosis and other demyelinating diseases.
• Provides a model for studying lipid metabolism and membrane biogenesis.
• Enables investigation of glycosphingolipid functions in cell signaling.
• Potential therapeutic target for remyelination strategies.
What Happens During N-acylsphingosine galactosyltransferase activity?
Substrate Recognition and Binding
In simple terms: The enzyme grabs ceramide and UDP-galactose to start the reaction.
The enzyme ceramide galactosyltransferase (CGT) binds its substrates, N-acylsphing-4-enine (ceramide) and UDP-alpha-D-galactose, in the endoplasmic reticulum or Golgi apparatus. This binding is highly specific, ensuring that galactose is transferred to ceramide rather than other acceptors.
Catalytic Transfer of Galactose
In simple terms: The enzyme moves galactose from UDP-galactose onto ceramide.
CGT catalyzes the transfer of galactose from UDP-alpha-D-galactose to the primary hydroxyl group of ceramide, forming beta-D-galactosyl-(1<->1')-N-acylsphing-4-enine (galactosylceramide) and releasing UDP and a proton. This reaction is a key step in the synthesis of galactosylceramide and sulfatide.
Product Formation and Release
In simple terms: The new lipid molecule is released and used in myelin.
The product galactosylceramide is released from the enzyme and subsequently transported to myelin membranes, where it contributes to the lipid-rich environment of myelin sheaths. It can be further sulfated to form sulfatide, another essential myelin lipid.
Regulation of Enzyme Activity
In simple terms: The amount and activity of the enzyme are controlled by other proteins.
CGT expression is positively regulated by the transcription factor Nkx2.2 and negatively regulated by OLIG2, which influences oligodendrocyte differentiation and myelination. Additionally, the enzyme's activity may be modulated by the availability of substrates and the lipid environment.
Key Genes Involved in GO:0003851 N-acylsphingosine galactosyltransferase activity
The following genes and proteins are directly involved in N-acylsphingosine galactosyltransferase activity or its regulation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| UGT8 | Encodes ceramide galactosyltransferase (CGT), the enzyme catalyzing the reaction | Central to galactosylceramide synthesis; knockout causes demyelination |
| Nkx2.2 | Transcription factor that positively regulates CGT expression | Promotes oligodendrocyte differentiation and myelination |
| OLIG2 | Transcription factor that negatively regulates CGT expression | Inhibits premature myelination; balances oligodendrocyte development |
| PGRMC1 | Progesterone receptor membrane component 1; antagonist AG-205 inhibits galactosylceramide synthesis | Potential regulator of CGT activity |
| FASN | Fatty acid synthase; involved in lipid synthesis during myelination | Provides fatty acids for myelin lipids |
| MBP | Myelin basic protein; structural component of myelin | Marker of myelination; affected in demyelination models |
| PLP1 | Proteolipid protein 1; major myelin protein | Mutations cause leukodystrophy; interacts with galactolipids |
| UGCG | Ceramide glucosyltransferase; catalyzes first glycosylation step of glycosphingolipids | Related enzyme; provides contrast for galactosyltransferase studies |
| CGT | Ceramide galactosyltransferase (protein) | Direct enzyme; target for knockout and overexpression |
| Sulfatide | Sulfated galactosylceramide; product of CGT activity | Essential myelin lipid; marker of myelination |
| Galactosylceramide | Product of CGT activity | Major myelin lipid; used to assess enzyme function |
| Cholesterol | Lipid regulated in Schwann cells; linked to CGT pathway | Studied in demyelination contexts |
| Cuprizone | Chemical used to induce demyelination in models | Used to study remyelination and CGT expression |
| AG-205 | PGRMC1 antagonist; inhibits galactosylceramide synthesis | Chemical tool to probe CGT pathway |
| UDP-galactose | Substrate for CGT | Donor of galactose in the reaction |
| Ceramide | Substrate for CGT | N-acylsphing-4-enine; precursor for galactosylceramide |
How Is N-acylsphingosine galactosyltransferase activity Regulated?
N-acylsphingosine galactosyltransferase activity is primarily regulated at the transcriptional level. The transcription factor Nkx2.2 positively regulates CGT expression, promoting myelination, while OLIG2 negatively regulates it, preventing premature myelination. Additionally, the PGRMC1 antagonist AG-205 inhibits the synthesis of galactosylceramide and sulfatide, suggesting that PGRMC1 may play a role in regulating this pathway. Cholesterol biosynthesis in Schwann cells may also influence CGT activity, as both are involved in myelin lipid metabolism.
N-acylsphingosine galactosyltransferase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| UGT8 | Demyelinating diseases (e.g., leukodystrophy) | UGT8 knockout mouse; patient-derived iPSCs |
| Nkx2.2 | Myelination disorders | Nkx2.2 knockout and overexpression in oligodendrocyte precursors |
| OLIG2 | Myelination disorders | OLIG2 knockout and overexpression in oligodendrocyte precursors |
| PGRMC1 | Lipid metabolism disorders | PGRMC1 knockout cells treated with AG-205 |
| FASN | Peripheral neuropathy | FASN conditional knockout in Schwann cells |
Demyelinating Diseases
Reduced or absent N-acylsphingosine galactosyltransferase activity leads to deficiencies in galactosylceramide and sulfatide, causing severe demyelination in the central and peripheral nervous systems. This is observed in diseases such as multiple sclerosis and leukodystrophies, where myelin integrity is compromised.
Neurological Disorders
Mutations in the UGT8 gene or dysregulation of CGT expression can result in neurological impairments, including motor deficits and cognitive decline, due to impaired myelin formation. Animal models with CGT deficiency exhibit tremors and ataxia.
Cancer and Lipid Metabolism
Altered glycosphingolipid metabolism, including galactosylceramide synthesis, has been implicated in cancer progression and drug resistance, though the specific role of CGT in cancer requires further investigation.
From N-acylsphingosine galactosyltransferase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the effect of UGT8 loss on myelination? | UGT8 knockout mouse or human iPSC-derived oligodendrocytes |
| How does Nkx2.2 regulate CGT expression? | Nkx2.2 overexpression and knockdown in oligodendrocyte precursor cells |
| Does a point mutation in UGT8 affect enzyme activity? | CRISPR point-mutation knock-in of specific UGT8 variants |
| Can tagged CGT be used to study localization? | Knock-in of fluorescent or epitope tags into UGT8 locus |
| What is the effect of CGT overexpression on lipid levels? | Overexpression of UGT8 in cell lines or transgenic mice |
| How does PGRMC1 inhibition affect galactosylceramide synthesis? | PGRMC1 knockout cells treated with AG-205 |
How to Study the N-acylsphingosine galactosyltransferase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS/MS | Galactosylceramide and sulfatide levels | Quantifying lipid changes in knockout models |
| Radioactive enzyme assay | CGT enzymatic activity | Kinetic studies and inhibitor screening |
| qRT-PCR | UGT8 mRNA expression | Assessing transcriptional regulation |
| RNA-seq | Global gene expression changes | Identifying pathways affected by CGT loss |
| Immunohistochemistry | Myelin proteins and lipids | Visualizing demyelination in tissue sections |
| Western blot | CGT protein levels | Validating knockout or overexpression |
| CRISPR screening | Genes affecting galactosylceramide synthesis | Identifying novel regulators |
| Bioinformatics | Pathway enrichment and network analysis | Interpreting omics data from CGT models |
Lipid Analysis by Mass Spectrometry
Mass spectrometry (e.g., LC-MS/MS) is used to quantify galactosylceramide and sulfatide levels in cells or tissues, providing direct readout of CGT activity.
Enzymatic Activity Assays
In vitro assays using radiolabeled UDP-galactose and ceramide can measure CGT activity in membrane fractions, allowing kinetic studies and inhibitor testing.
Gene Expression Analysis
Quantitative RT-PCR and RNA-seq are used to measure UGT8 mRNA levels and identify transcriptional changes in myelination models.
Immunohistochemistry and Imaging
Antibodies against galactosylceramide or CGT can visualize myelin integrity and enzyme localization in tissue sections, aiding in demyelination studies.
How CRISPR Can Be Used to Study GO:0003851 N-acylsphingosine galactosyltransferase activity
Knockout
CRISPR knockout of UGT8 in cell lines or animal models abolishes CGT activity, leading to loss of galactosylceramide and sulfatide, and providing a system to study demyelination and lipid metabolism.
Point Mutation
Introducing specific point mutations in UGT8 via CRISPR can mimic human variants, allowing assessment of their impact on enzyme activity and myelin formation.
Knock-in
Knock-in of tags (e.g., FLAG, GFP) into the endogenous UGT8 locus enables real-time tracking of CGT localization and interaction partners without altering expression levels.
Overexpression
CRISPR activation (CRISPRa) or transgenic overexpression of UGT8 can increase galactosylceramide synthesis, useful for studying gain-of-function effects and potential therapeutic applications.
How EDITGENE Supports N-acylsphingosine galactosyltransferase activity Research
Researchers studying N-acylsphingosine galactosyltransferase activity-related genes often need to determine whether a candidate gene is causally involved in myelination, lipid metabolism, or disease. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell and animal models, accelerating functional validation and therapeutic development.
Contact EDITGENE today to design your custom CRISPR model for N-acylsphingosine galactosyltransferase activity research.
Frequently Asked Questions About N-acylsphingosine galactosyltransferase activity
What is N-acylsphingosine galactosyltransferase activity?
It is the enzymatic activity that transfers galactose from UDP-galactose to ceramide, forming galactosylceramide, a key myelin lipid.
What genes are involved in N-acylsphingosine galactosyltransferase activity?
The primary gene is UGT8, which encodes ceramide galactosyltransferase (CGT). Transcription factors Nkx2.2 and OLIG2 regulate its expression.
What is the role of UGT8 in myelination?
UGT8 is essential for synthesizing galactosylceramide and sulfatide, which are major components of myelin sheaths in the nervous system.
How is N-acylsphingosine galactosyltransferase activity regulated?
It is regulated transcriptionally by Nkx2.2 (positive) and OLIG2 (negative), and potentially by PGRMC1 and cholesterol biosynthesis.
What diseases are associated with defects in this activity?
Defects cause demyelinating diseases such as leukodystrophies and contribute to multiple sclerosis pathology.
What methods are used to study N-acylsphingosine galactosyltransferase activity?
Common methods include mass spectrometry for lipid analysis, enzyme activity assays, qRT-PCR, and immunohistochemistry.
Can CRISPR be used to study this activity?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools to dissect UGT8 function and regulation.
What is the reaction catalyzed by N-acylsphingosine galactosyltransferase?
N-acylsphing-4-enine + UDP-alpha-D-galactose = beta-D-galactosyl-(1<->1')-N-acylsphing-4-enine + H+ + UDP.
What are the products of this enzyme?
The products are galactosylceramide (beta-D-galactosyl-(1<->1')-N-acylsphing-4-enine), UDP, and a proton.
How does EDITGENE support research on this activity?
EDITGENE provides CRISPR knockout, point mutation, knock-in, overexpression models, library screening, and bioinformatics services for UGT8 and related genes.
Conclusion
N-acylsphingosine galactosyltransferase activity (GO:0003851) is a critical molecular function for the synthesis of galactosylceramide and sulfatide, essential for myelin integrity and nervous system function. Its regulation by Nkx2.2 and OLIG2 highlights its importance in developmental myelination. Dysregulation leads to demyelinating diseases, making it a key target for research and therapeutic development. Advanced CRISPR models and analytical methods continue to unravel its roles in health and disease.
References
- 1. Wang-Eckhardt L et al.. 2021. The PGRMC1 Antagonist AG-205 Inhibits Synthesis of Galactosylceramide and Sulfatide.. Cells 10(12) PMID: 34944026
- 2. Fu Q et al.. 1998. Control of cholesterol biosynthesis in Schwann cells.. J Neurochem 71(2):549-55 PMID: 9681444
- 3. Okahara K et al.. 2014. Ceramide galactosyltransferase expression is regulated positively by Nkx2.2 and negatively by OLIG2.. Glycobiology 24(10):926-34 PMID: 24821492
- 4. Kapitonov D et al.. 1997. Cloning, characterization, and expression of human ceramide galactosyltransferase cDNA.. Biochem Biophys Res Commun 232(2):449-53 PMID: 9125199
- 5. Zöller I et al.. 2005. Oligodendrocyte-specific ceramide galactosyltransferase (CGT) expression phenotypically rescues CGT-deficient mice and demonstrates that CGT activity does not limit brain galactosylceramide level.. Glia 52(3):190-8 PMID: 15968630
- 6. Salles J et al.. 2002. Fatty acid synthase expression during peripheral nervous system myelination.. Brain Res Mol Brain Res 101(1-2):52-8 PMID: 12007831
- 7. Morell P et al.. 1998. Gene expression in brain during cuprizone-induced demyelination and remyelination.. Mol Cell Neurosci 12(4-5):220-7 PMID: 9828087
- 8. Ichikawa S et al.. 1996. Expression cloning of a cDNA for human ceramide glucosyltransferase that catalyzes the first glycosylation step of glycosphingolipid synthesis.. Proc Natl Acad Sci U S A 93(10):4638-43 PMID: 8643456
